Daiichi Sankyo links up with Korea’s Alteogen on subcutaneous Enhertu in $300M licensing deal

CAR-T Digest - August 2020

8 Nov 2024: Daiichi Sankyo links up with Korea’s Alteogen on subcutaneous Enhertu in $300M licensing deal

Daiichi Sankyo has signed a licensing deal with Korea’s Alteogen worth up to $300 million to develop a subcutaneous version of its antibody-drug conjugate (ADC) Enhertu
The agreement includes a $20 million upfront payment from Daiichi Sankyo to Alteogen to use its ALT-B4 platform for the subcutaneous formulation of Enhertu
Additional commercial and development milestones could provide Alteogen with up to $280 million, along with royalties based on sales
The deal is conditional and subject to the success of clinical studies and regulatory approval for the new formulation
Enhertu, partnered with AstraZeneca, generated $2.5 billion in global sales in 2023, but its sales growth has stalled, partly due to issues in China and challenges with pricing in the UK
Alteogen’s ALT-B4 technology, which enables subcutaneous drug delivery, has attracted interest from multiple companies, including Merck, with which it has a separate licensing agreement for subcutaneous Keytruda